MiMedx
1234 Airport Road
Suite 105
Destin
Florida
32541
United States
Tel: 850-269-0000
Website: http://www.mimedx.com/
456 articles about MiMedx
-
MIMEDX Announces First Quarter 2023 Operating and Financial Results
5/2/2023
MiMedx Group, Inc., a pioneer and leader in placental biologics, announced operating and financial results for the first quarter 2023, which ended March 31, 2023, including net sales of $71.7 million, net loss of $5.0 million and Adjusted EBITDA of $5.5 million.
-
MIMEDX Announces Chief Financial Officer Transition
3/23/2023
MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities.
-
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director
1/30/2023
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that its Board of Directors has appointed Joseph H. Capper as the Company’s Chief Executive Officer and a director of the Company, effective immediately.
-
MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
1/9/2023
MiMedx Group, Inc., a pioneer and leader in placental biologics, provided the following updates about its business.
-
MIMEDX Announces Commercial Launch of EPIFIX® in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
1/4/2023
MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it has entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED, a subsidiary of Gunze Limited, for sales of EPIFIX in Japan.
-
MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer
1/3/2023
MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s manufacturing, supply chain, procurement, quality, and regulatory functions.
-
MIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
12/8/2022
MiMedx Group, Inc. today announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform, PermaFusion®, for the development of future biologic products focused on wound and surgical recovery applications.
-
MIMEDX to Present at Upcoming Investor Conferences
11/10/2022
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the following investor conferences.
-
MIMEDX Announces Third Quarter 2022 Operating and Financial Results
11/2/2022
MiMedx Group, Inc., a transformational placental biologics company, announced operating and financial results for the third quarter 2022, which ended September 30, 2022.
-
MIMEDX Appoints Matt Notarianni as Head of Investor Relations
10/4/2022
MiMedx Group, Inc., a transformational placental biologics company, announced the appointment of Matt Notarianni as Head of Investor Relations, effective immediately.
-
MIMEDX Announces Launch of AXIOFILL™
9/20/2022
MiMedx Group, Inc., a transformational placental biologics company, announced the launch of AXIOFILL™, an Extracellular Matrix Particulate product derived from human placental tissue.
-
MIMEDX Announces Launch of AMNIOEFFECT™
9/19/2022
MiMedx Group, Inc. today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.
-
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.
-
Regenerative Engineering Society Establishes Award in Honor of MIMEDX Board Member, Dr. Cato T. Laurencin
8/26/2022
The Cato T. Laurencin Regenerative Engineering Founders’ Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering.
-
MIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts
7/27/2022
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the formation of a Regenerative Medicine Scientific Advisory Board.
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers.
-
MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
7/20/2022
MiMedx Group, Inc., a transformational placental biologics company, announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022.
-
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer
7/18/2022
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Human Resources Officer (CHRO), effective today.
-
MIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting
6/7/2022
MiMedx Group, Inc. announced that, based on the preliminary vote count provided by its proxy solicitor, shareholders have approved all proposals set forth by the Company at the 2022 Annual Meeting of Shareholders, including the reelection of both of MIMEDX’s directors, Dr. Phyllis Gardner and James L. Bierman, and the proposals on say-on-pay and the Company’s qualified employee stock purchase plan.
-
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders
6/3/2022
MiMedx Group, Inc., a transformational placental biologics company, reminded shareholders to pre-register for the upcoming 2022 Annual Meeting of Shareholders, by no later than 9:00 a.m. Eastern Time on Monday, June 6, 2022.